Amyris Inc

Amyris — Investor Presentation (March 2020)

29 slides from Amyris's investor presentation, Mar 16, 2020

  1. Slide 1: Amyris, Inc.

    = L Amyris, Inc. March 16, 2020 amyris

  2. Slide 2: Cautionary Notes

    Cautionary Notes Cautionary Notes FORWARD-LOOKING STATEMENTS This presentation and oral statements accompanying this presentation contain forward-looking statements, and any statements other than statements of historical fact could be deemed to be forward-looking statements. These forward-looking st

  3. Slide 3: Amyris: Make good. No compromise.

    amyris Make good. No compromise.®

  4. Slide 4: We Are on a Mission to Make Our Planet Healthier

    We Are on a Mission to Make Our Planet Healthier  A consumer driven company powered by a leading life sciences platform  The fastest growing skin care brand in North America  The world’s leading synthetic biology platform making sustainable ingredients accessible to the world’s leading brands for

  5. Slide 5: A Business Model Delivering Growth and Strong Margins

    A Business Model Delivering Growth and Strong Margins Consumer Health and Beauty Brands Brands Key Financial Metrics Fastest Growing Clean Beauty Business 2018-2020P Revenue CAGR ~160% in North America 2020P Gross Margin 66% Clean, Sustainable Ingredients Ingredients Key Financial Metrics #1 Supplie

  6. Slide 6: Business Model Creates Value for Partners & Customers

    Business Model Creates Value for Partners & Customers PROVEN TECH PLATFORM VALUE CREATION MODEL Ingredients: Apply Synthetic Biology to • Farnesene Making Natural Ingredients • Patchouli • Squalane • Sclareol Platform • Manool Ingredients Disruptive • Bisabolol • Fragrance 5* Product • Flavor 1* Eff

  7. Slide 7: Strong & Sustainable Growth

    Strong & Sustainable Growth Doubling Recurring Revenue Yearly and over 30% Adj EBITDA by 2022 Amyris Total Revenue ($M) Technology Collaborations Product Revenue & Royalties $220* $153 $64 2018 2019P 2020P 2021P 2022P 2023P Gross Profit % 57% 56% 60-70% 65-70% 65-70% 65-70% *With potential upside of

  8. Slide 8: 2019 Financial Highlights

    2019 Financial Highlights 2019 Actuals 2018 Actuals Revenue Product Revenue $59.9M $33.6M Licenses & Royalties $54.0M $7.7M Collaborations & Grants $38.6M $22.3M Total $152.6M $63.6M Non- GAAP % Gross Profit 56.0% 56.9% Adjusted EBITDA (i,ii) (i) Excludes depreciation & amortization and stock compen

  9. Slide 9: Current Business and Pipeline Gross Profit Performance

    Current Business and Pipeline Gross Profit Performance 2018 4Q2019 2020 2021 2022 2023 Current Business Product Gross Profit $ MM$ 13.90 $ 6.88 $ 57.80 $ 156.75 $ 255.36 $ 367.21 Product Gross Profit % 34% 36% 40% 40% 55% 57% Current Gross Profit $ MM$ 36.20 $ 22.66 $ 168.80 $ 240.55 $ 307.86 $ 419.

  10. Slide 10: We have ~57 MM of Warrants – about 75% owned by insiders

    We have ~57 MM of Warrants – about 75% owned by insiders Cash From Warrants Total Shares Categories Strike price Shares (M) ($M) (M) Common Shares Outstanding 163.8 Warrants: $ 0.015 6.3$ 0.94 $ 2.87 34.0$ 97.48 Warrant Expirations # of $ 3.25 3.0$ 9.75 by Year % Warrants Cash $ 3.87 2.0$ 7.74 2020

  11. Slide 11: Debt Schedule

    Debt Schedule © 2020 Amyris, Inc. All rights reserved. 11

  12. Slide 12: We Have Production Resilience to Deliver Through Coronavirus

    We Have Production Resilience to Deliver Through Coronavirus Production Volume Scenarios (MT) 1200 Inventory Scenarios (MT) 1600 1000 1400 1200 800 Inventory can 1000 600 Supply Q2 800 sales 600 400 400 200 Modeled 0 MT 200 in Q2 0 0 EOY 2019 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2020 Plan Corona Virus Scenario 2

  13. Slide 13: Amyris Technology Accelerating Industry Disruption

    Amyris Technology Accelerating Industry Disruption Key Technical Metrics Amyris Global Market Opportunities ($B) 350 Molecules commercialized per year 2-4 $323B TAM Number of PhD’s ~85 Number of US and foreign patents issued and 300 871 applications pending Amyris CAGR Molecules Manufactured 10 250

  14. Slide 14: Industry Leading Growth and Gross Margin Driven By Technology Leadership

    Industry Leading Growth and Gross Margin Driven By Technology Leadership Industrialized Synthetic Biology Delivery in 12 Months Full Cycle Clean Fermentation Produces Sustainable Molecules At Scale © 2020 Amyris, Inc. All rights reserved. 14

  15. Slide 15: DARPA Funding Helped Create Our Synthetic Leadership in the US

    DARPA Funding Helped Create Our Synthetic Leadership in the US >100 molecules >20 molecules $8M DARPA Award; $36M DARPA Award; produced at produced at > 10 mg/L Living Foundries ATCG Designed 535 molecules > 25 mg/L scale scale 18 delivered to DoD Completion of Living 247 molecules produced >50 mole

  16. Slide 16: Clean Beauty

    Clean Beauty

  17. Slide 17: The Leading Beauty Brand in Sustainability

    The Leading Beauty Brand in Sustainability RENEWABLE RESOURCE CLEAN NO DEFORESTATION BEAUTY LOW WATER USAGE DOWN TO A SCIENCE CRUELTY-FREE & VEGAN RECYCLABLE NONTOXIC

  18. Slide 18: Leading Supplier of Clean Ingredients to the Beauty Industry

    Leading Supplier of Clean Ingredients to the Beauty Industry: We are Setting the Standard with Biossance We supply the world’s leading brands Our brand sets the standard for consumers Cosmetic Ingredient Sales Biossance Consumer Sell-through Volume Through Primary Distributors Differentiators that E

  19. Slide 19: Biossance is on Track to Become a Billion Dollar Brand

    Biossance is on Track to Become a Billion Dollar Brand Biossance Key Growth Drivers DOORS SALES Sephora End Caps produces 2-2.5X more retail revenue Sephora Monthly Productivity* Dec 2018 = 104% 297 296 255 240 113 130 June 2019 = 141% 2017 2018 2019 YE Dec 2019 = 135% EC (17 SKUs) Wall (6SKUs) Jan

  20. Slide 20: Baby skincare launch and retail channel distribution

    Launched September 4, 2019 • EWG Verified™ • Leaping Bunny Approved Retail Channel Distribution • Dermatologist tested • Pediatrician approved • Hypoallergenic • Nontoxic • Vegan • Synthetic fragrance-free 20 Copyright © 2020 Amyris, Inc. All rights reserved

  21. Slide 21: Health & Ingredients

    Health & Ingredients Health & Ingredients

  22. Slide 22: Growing our Sustainable Health & Ingredients Business

    Growing our Sustainable Health & Ingredients Business FRAGRANCE FLAVOR Delivering Sustainable Fragrances Delivering a Revolutionary Sweetener • Global partners choose Amyris to develop sustainable ingredients they could not scale on their own Amyris Sweetener • We supply 3 of the Top 5 Flavors & Fra

  23. Slide 23: Purecane: Meet the New Sweet

    purecane MEET THE NEW SWEET. We discovered a revolutionary way to ferment sugarcane, bringing you the purest no-calorie sweetness in the world.

  24. Slide 24: Amyris is Disrupting the Sweetener Market

    Amyris is Disrupting the Sweetener Market SWEETNESS EQUIVALENCY 100% SWEET 100% SUSTAINABLE 350-500 grams of sugar* 1 gram of Reb M 0 bitter aftertaste responsibly grown sugarcane 0 glycemic index 10x less farmland to produce 0 calories 1 clean fermentation process 0 GMO all recycled cane-based pack

  25. Slide 25: Cannabinoids: Establishing Market Leadership For Sustainable Health

    Cannabinoids: Establishing Market Leadership For Sustainable Health •Up to $300M cannabinoids collaboration with LAVVAN with plans to commercialize Clean CBD & CBG in 2020 •Delivering cannabinoids at significant cost advantage with ultra purity, which is essential for accelerating brand adoption •We

  26. Slide 26: Synthetic Biology Competitive Landscape

    Synthetic Biology Competitive Landscape Fermentation Total Equity 2019 Annual Enterprise Products Commercial Capital Annual Growth Rate Value Currently in Visibility Invested Revenue (2018-2019) Production Amyris $670M ~$1B* $153M 140% 10 Gingko $4B(est) $719M $80M(est) 100%(est) 2(est) Zymergen $1B

  27. Slide 27: Select Executive Team & Board of Director Members

    Select Executive Team & Board of Director Members Amyris Executive Team Members include: John Melo Eduardo Alvarez Sunil Chandran Catherine Gore Caroline Hadfield President & CEO Chief Operation Officer SVP, R&D President, Biossance President, Pipette & Aprinnova Previous: BP Plc, Ernst & Previous:

  28. Slide 28: Environmental, Social, and Governance (ESG) at Amyris

    Environmental, Social, and Governance (ESG) at Amyris ESG* data is most often categorized as “non-accounting” information because it captures components important for valuations that are not traditionally reported. The valuation of companies has become more complex, with a growing portion tied up in

  29. Slide 29: Closing summary: Make good. No compromise.

    • Our ingredients are inside over $10B of consumer retail purchases sold through 3,000+ of the world’s leading Make good. personal care and beauty brands • Our Biossance Skin Care Brand is the ™ fastest growing Skin Care Brand in No compromise. North America • We have the leading product in the Good

Amyris — Investor Presentation (March 2020) on 6ix